Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon

SOBRE EL AUTOR **

My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

Thursday, July 8, 2021

Methoxyflurane

CanadiEM - By Jeremi Laski - July 8, 2021
Conclusion
Methoxyflurane, despite its volatile history as an anesthetic (pun intended), has a promising future as an analgesic agent both in the pre-hospital and ED setting. While research is still emerging, including Health Canada trials for use in Canada, many studies have demonstrated both its effectiveness as an analgesic and the added advantages of its portability and non-invasive administration. 
N.B. There is a lack of evidence for whether methoxyflurane inhaler use is an aerosol generating medical procedure; clinicians should consider methoxyflurane use in the broader context of COVID-19 and potential aerosol generation with inhaler use.
Key Takeaways 
Methoxyflurane is a promising non-opioid, non-invasive analgesic that can effectively reduce mild to severe pain in an ED setting. Administer via MDI up to 3 puffs. Care should be taken to avoid giving it to patients with pre existing renal conditions.